Glaxo malaria vaccine protects babies, children
By Maggie Fox, Health and Science Editor
WASHINGTON (Reuters) - An experimental malaria vaccine is the most promising yet, protecting up to 65 percent of infants from infection in two studies in Africa, researchers reported on Monday.
Separate tests in Kenya and Tanzania showed GlaxoSmithKline’s vaccine called RTS,S could protect babies and toddlers from infection with malaria and could prevent disease even in those already infected.
While the vaccine is far from perfect, it is the best yet against the mosquito-borne parasite, the researchers agreed. They said they would now begin phase III clinical tests, the last stage before seeking regulatory approval, next year.
“Even a partially effective vaccine has the potential to save hundreds of thousands of lives each year,” said Christian Loucq, director of the nonprofit PATH Malaria Vaccine Initiative, which helped to conduct the study.
“We are one important step closer to the date when malaria will join diseases such as smallpox and polio, which have been either eliminated or controlled through vaccines,” Loucq said.
The World Health Organization estimates malaria killed 881,000 people and infected 247 million worldwide in 2006. Some malaria experts say those numbers underestimate the problem.
The disease is especially hard to fight as people are continually infected by mosquitoes throughout their lives. The tiny parasites get into the blood and live and reproduce inside the body, causing fever and sometimes deadly brain infections.
Dr. Salim Abdulla of the Bagamoyo Research and Training Center in Tanzania and colleagues tested 340 infants, giving them three doses of the RTS,S vaccine or three doses of hepatitis B vaccine.
The malaria vaccine protected 65 percent of infants from infection with malaria during the six months of the trial.
“We are very confident that the efficacy of the vaccine extends for several years,” Joe Cohen of GlaxoSmithKline Biologicals in Belgium told the briefing.
An earlier study had shown the vaccine could protect children for at least 18 months.
The children also got vaccines against diphtheria, tetanus, whooping cough and Haemophilus influenzae B as part of a World Health Organization childhood vaccination program and the vaccines all worked well, the study showed.
In a second trial, Dr. Ally Olutu of the KEMRI-Wellcome Trust Collaborative Research Center in Kenya and colleagues vaccinated 894 children aged 5 to 17 months with three doses of either a slightly different formulation of the malaria vaccine or a rabies vaccine.
The found clinical episodes of malaria fell by 53 percent.
While this is slightly different from complete protection from infection, the researchers said the point is to protect children from disease and they felt the results were comparable.
(Editing by John O’Callaghan)
--------------------------------------------------------------------------------------------Related Posts:
By Will Dunham WASHINGTON (Reuters) - U.S. health officials asked doctors on Thursday to be alert for possible cases of meningitis and other illnesses in children caused by Hib bacteria amid an ongoing vaccine shortage. Officials are most concerned about bacterial meningitis and sepsis, a bloodstream infection, caused by Hib (Haemophilus influenzae type b) in children under
Full Post: Doctors to be on guard for meningitis in kids
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - A vaccine to protect against infection with the bird flu virus, the pathogen experts fear is capable of causing pandemic disease in humans, proved safe and effective in a preliminary clinical trial with children, mirroring the results of a recent trial conducted in adults, Hungarian researchers report in the Pediatric
Full Post: Bird flu vaccine protects children
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - A combination vaccine against diphtheria, tetanus, pertussis, polio and flu, which is routinely used in Canadian children, has been shown to be effective and well tolerated in a U.S. study. The randomized trial was conducted to support U.S. licensure of the vaccine known as DTaP5-IPV-Hib, which incorporates diphtheria-tetanus-5-component acellular pertussis (DTaP5),
Full Post: Combination vaccine safe and effective for infants
--------------------------------------------------------------------------------------------
By Megan Rauscher NEW YORK (Reuters Health) - Even in an influenza season where there is not an optimal match between circulating strains of influenza and the strains contained in the influenza vaccine, the vaccine is likely to significantly protect young children, ages 6 to 59 months, against influenza, new research indicates. Influenza vaccine effectiveness has not
Full Post: Influenza vaccine effective in young children
--------------------------------------------------------------------------------------------
By Gene Emery BOSTON (Reuters) - A newer vaccine that targets the most common form of the polio virus works up to four times better than the conventional vaccine that tries to protect against all three types of the crippling disease, researchers said on Wednesday. The monovalent vaccine may help speed the fight to eradicate polio, U.S.
Full Post: Newer vaccine seen as better for polio hot spots